Bruker Announces 1.2 GHz NMR Spectrometer at Swiss High-field NMR Facility
Bruker announces the installation of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, jointly operated by the University of Basel, ETH Zürich, and the University of Zürich. This is Switzerland's second 1.2 GHz NMR, complementing existing equipment including an 800 MHz NMR in Basel.
The new instrument will enhance research capabilities in structural biology and macromolecular analysis, specifically enabling detailed studies of G protein-coupled receptors (GPCRs), intrinsically disordered proteins, and RNA research. The facility will support various applications including protein structure determination, dynamics measurement, ligand binding studies, and protein-protein interaction analysis.
Bruker annuncia l'installazione di uno spettrometro di risonanza magnetica nucleare (NMR) Ascend™ da 1,2 GHz presso la Swiss High-field NMR Facility, gestita congiuntamente dall'Università di Basilea, dall'ETH di Zurigo e dall'Università di Zurigo. Questo è il secondo NMR da 1,2 GHz in Svizzera, che si aggiunge alle attrezzature esistenti, tra cui un NMR da 800 MHz a Basilea.
Il nuovo strumento potenzierà le capacità di ricerca in biologia strutturale e analisi macromolecolare, consentendo studi dettagliati su recettori accoppiati a proteine G (GPCR), proteine intrinsecamente disordinate e ricerca sull'RNA. La struttura sosterrà varie applicazioni tra cui la determinazione della struttura delle proteine, la misurazione della dinamica, studi sul legame degli ligandi e l'analisi delle interazioni proteina-proteina.
Bruker anuncia la instalación de un espectrómetro de resonancia magnética nuclear (NMR) Ascend™ de 1,2 GHz en la Instalación Suiza de NMR de Alto Campo, operada conjuntamente por la Universidad de Basilea, la ETH de Zúrich y la Universidad de Zúrich. Este es el segundo NMR de 1,2 GHz en Suiza, complementando el equipo existente que incluye un NMR de 800 MHz en Basilea.
El nuevo instrumento mejorará las capacidades de investigación en biología estructural y análisis macromolecular, permitiendo estudios detallados de receptores acoplados a proteínas G (GPCR), proteínas intrínsecamente desordenadas y la investigación de RNA. La instalación apoyará diversas aplicaciones que incluyen la determinación de la estructura de proteínas, mediciones de dinámica, estudios de unión de ligandos y análisis de interacciones proteína-proteína.
브루커는 바젤 대학교, 취리히 연방공과대학교(ETH Zürich), 취리히 대학교가 공동 운영하는 스위스 고자기장 NMR 시설에 1.2 GHz Ascend™ 핵자기 공명(NMR) 분광기를 설치했다고 발표했습니다. 이는 스위스의 두 번째 1.2 GHz NMR로, 바젤에 있는 800 MHz NMR을 포함한 기존 장비를 보완합니다.
이 새로운 기기는 구조 생물학 및 거대 분자 분석의 연구 능력을 향상시키며, G 단백질 결합 수용체(GPCR), 본질적으로 무질서한 단백질 및 RNA 연구에 대한 자세한 연구를 가능하게 합니다. 이 시설은 단백질 구조 결정, 동역학 측정, 리간드 결합 연구 및 단백질-단백질 상호작용 분석을 포함한 다양한 응용 활동을 지원할 것입니다.
Bruker annonce l'installation d'un spectromètre de résonance magnétique nucléaire (RMN) Ascend™ de 1,2 GHz à la Suisse High-field NMR Facility, exploitée conjointement par l'Université de Bâle, l'ETH Zurich et l'Université de Zurich. Il s'agit du deuxième RMN de 1,2 GHz en Suisse, complétant l'équipement existant, y compris un RMN de 800 MHz à Bâle.
Le nouvel instrument améliorera les capacités de recherche en biologie structurale et en analyse macromoléculaire, permettant des études détaillées sur les récepteurs couplés aux protéines G (GPCR), les protéines intrinsèquement désordonnées et la recherche sur l'ARN. La structure soutiendra diverses applications, y compris la détermination de la structure des protéines, la mesure de la dynamique, les études de liaison des ligands et l'analyse des interactions protéine-protéine.
Bruker kündigt die Installation eines 1,2 GHz Ascend™ Kernspinresonanz (NMR) Spektrometers in der Schweizer Hochfeld-NMR-Anlage an, die gemeinsam von der Universität Basel, der ETH Zürich und der Universität Zürich betrieben wird. Dies ist der zweite 1,2 GHz NMR in der Schweiz und ergänzt die bestehende Ausstattung, einschließlich eines 800 MHz NMR in Basel.
Das neue Gerät wird die Forschungskapazitäten in der strukturellen Biologie und der makromolekularen Analyse verbessern und ermöglicht detaillierte Studien zu G-Protein-gekoppelten Rezeptoren (GPCRs), intrinsisch ungeordneten Proteinen und RNA-Forschung. Die Einrichtung wird verschiedene Anwendungen unterstützen, einschließlich der Bestimmung von Proteinstrukturen, der Messung von Dynamiken, der Untersuchung von Ligandenbindungen und der Analyse von Protein-Protein-Interaktionen.
- Installation of advanced 1.2 GHz NMR spectrometer expanding Bruker's presence in high-end research facilities
- Strategic placement in prestigious Swiss research institutions strengthening market position
- Technology enables new research applications in pharmaceutical and disease-related studies
- None.
Insights
State-of-the-art instrument enhances research in structural biology and protein analysis
ZÜRICH--(BUSINESS WIRE)--
Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, operated jointly by the University of
New 1.2 GHz Avance® at UZH site of the Swiss High-Field NMR Facility (Photo: Business Wire)
The Swiss High-field NMR Facility has locations at Biozentrum Basel and at University of
Professor Oliver Zerbe from University of
Stephan Grzesiek, Professor of Structural Biology at Biozentrum Basel, who started the initiative for a Swiss high-field solution NMR, remarked: “Finally, we also have a highest-field NMR available for Swiss solution NMR. It will enable new NMR methods and explore the limits of detection in disease-relevant applications, such as GPCR signaling and cancer.”
His colleague, Professor Sebastian Hiller from Biozentrum Basel noted: "The 1.2 GHz NMR allows to study structures and dynamics of chaperone-client complexes at atomic resolution. These detailed descriptions will reveal biophysical laws governing chaperone function, with implications for neurodegenerative diseases, such as Parkinson’s."
Detlef Günther, Professor for Trace Element and Micro Analysis, and Vice President of Research at ETH Zürich (2015-2022) when the instrument was ordered, remarked: "We are excited to provide our scientists with this ultra-high field NMR. This collaboration will enable groundbreaking research in structural biology, furthering our understanding of complex biological systems.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241220748125/en/
Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com
Source: Bruker Corporation
FAQ
What capabilities does Bruker's new 1.2 GHz NMR spectrometer offer for research?
How many 1.2 GHz NMR systems does Switzerland now have from BRKR?
What existing NMR infrastructure does the new BRKR 1.2 GHz system complement?
What specific disease research will the new BRKR 1.2 GHz NMR system support?
